A review by Australia's pharmaceutical regulator has raised concerns about "endocrine disruptors" in some sunscreens. Is ...

Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth ...

The proof points we are seeing across the business give us confidence that we have transitioned beyond stabilizing the ...